399 related articles for article (PubMed ID: 33301706)
41. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
Sangkhae V; Etheridge SL; Kaushansky K; Hitchcock IS
Blood; 2014 Dec; 124(26):3956-63. PubMed ID: 25339357
[TBL] [Abstract][Full Text] [Related]
42. Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation.
Jacquelin S; Straube J; Cooper L; Vu T; Song A; Bywater M; Baxter E; Heidecker M; Wackrow B; Porter A; Ling V; Green J; Austin R; Kazakoff S; Waddell N; Hesson LB; Pimanda JE; Stegelmann F; Bullinger L; Döhner K; Rampal RK; Heckl D; Hill GR; Lane SW
Blood; 2018 Dec; 132(26):2707-2721. PubMed ID: 30366920
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of ALK5 inhibition in myelofibrosis.
Yue L; Bartenstein M; Zhao W; Ho WT; Han Y; Murdun C; Mailloux AW; Zhang L; Wang X; Budhathoki A; Pradhan K; Rapaport F; Wang H; Shao Z; Ren X; Steidl U; Levine RL; Zhao ZJ; Verma A; Epling-Burnette PK
JCI Insight; 2017 Apr; 2(7):e90932. PubMed ID: 28405618
[TBL] [Abstract][Full Text] [Related]
44. Primary myelofibrosis and its targeted therapy.
Shantzer L; Berger K; Pu JJ
Ann Hematol; 2017 Apr; 96(4):531-535. PubMed ID: 27539616
[TBL] [Abstract][Full Text] [Related]
45. Megakaryocytes in Myeloproliferative Neoplasms Have Unique Somatic Mutations.
Guo BB; Allcock RJ; Mirzai B; Malherbe JA; Choudry FA; Frontini M; Chuah H; Liang J; Kavanagh SE; Howman R; Ouwehand WH; Fuller KA; Erber WN
Am J Pathol; 2017 Jul; 187(7):1512-1522. PubMed ID: 28502479
[TBL] [Abstract][Full Text] [Related]
46. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.
Ozono Y; Shide K; Kameda T; Kamiunten A; Tahira Y; Sekine M; Akizuki K; Nakamura K; Iwakiri H; Sueta M; Hidaka T; Kubuki Y; Yamamoto S; Hasuike S; Sawaguchi A; Nagata K; Shimoda K
Leukemia; 2021 Feb; 35(2):454-467. PubMed ID: 32472085
[TBL] [Abstract][Full Text] [Related]
47. pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms.
Wiśniewska-Chudy E; Szylberg Ł; Dworacki G; Mizera-Nyczak E; Marszałek A
Oncol Rep; 2017 Apr; 37(4):2295-2307. PubMed ID: 28260027
[TBL] [Abstract][Full Text] [Related]
48. The effects of hematopoietic stem cell transplant on splenic extramedullary hematopoiesis in patients with myeloproliferative neoplasm-associated myelofibrosis.
Pizzi M; Gergis U; Chaviano F; Orazi A
Hematol Oncol Stem Cell Ther; 2016 Sep; 9(3):96-104. PubMed ID: 27521149
[TBL] [Abstract][Full Text] [Related]
49. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
Mercier F; Monczak Y; François M; Prchal J; Galipeau J
Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
[TBL] [Abstract][Full Text] [Related]
50. Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology.
Eran Z; Zingariello M; Bochicchio MT; Bardelli C; Migliaccio AR
F1000Res; 2019; 8():. PubMed ID: 31583083
[TBL] [Abstract][Full Text] [Related]
51. Sinister symbiosis: pathological hematopoietic-stromal interactions in CML.
Mullally A; Ebert BL
Cell Stem Cell; 2013 Sep; 13(3):257-8. PubMed ID: 24012363
[TBL] [Abstract][Full Text] [Related]
52. Cellular senescence induced by S100A9 in mesenchymal stromal cells through NLRP3 inflammasome activation.
Shi L; Zhao Y; Fei C; Guo J; Jia Y; Wu D; Wu L; Chang C
Aging (Albany NY); 2019 Nov; 11(21):9626-9642. PubMed ID: 31727865
[TBL] [Abstract][Full Text] [Related]
53. Bone marrow-specific loss of
Chorzalska A; Morgan J; Ahsan N; Treaba DO; Olszewski AJ; Petersen M; Kingston N; Cheng Y; Lombardo K; Schorl C; Yu X; Zini R; Pacilli A; Tepper A; Coburn J; Hryniewicz-Jankowska A; Zhao TC; Oancea E; Reagan JL; Liang O; Kotula L; Quesenberry PJ; Gruppuso PA; Manfredini R; Vannucchi AM; Dubielecka PM
Blood; 2018 Nov; 132(19):2053-2066. PubMed ID: 30213875
[TBL] [Abstract][Full Text] [Related]
54. Properties of myelofibrosis-derived fibroblasts.
Castro-Malaspina H; Jhanwar SC
Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
[TBL] [Abstract][Full Text] [Related]
55.
Xiao P; Dolinska M; Sandhow L; Kondo M; Johansson AS; Bouderlique T; Zhao Y; Li X; Dimitriou M; Rassidakis GZ; Hellström-Lindberg E; Minato N; Walfridsson J; Scadden DT; Sigvardsson M; Qian H
Blood Adv; 2018 Mar; 2(5):534-548. PubMed ID: 29514790
[TBL] [Abstract][Full Text] [Related]
56. CD34+ stem cells in chronic myeloproliferative disorders.
Thiele J; Kvasnicka HM
Histol Histopathol; 2002 Apr; 17(2):507-21. PubMed ID: 11962756
[TBL] [Abstract][Full Text] [Related]
57. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
58. Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: deconstructing a myth?
Barosi G; Gale RP
Leuk Res; 2011 May; 35(5):563-5. PubMed ID: 21296418
[TBL] [Abstract][Full Text] [Related]
59. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
60. Adipogenic Mesenchymal Stromal Cells from Bone Marrow and Their Hematopoietic Supportive Role: Towards Understanding the Permissive Marrow Microenvironment in Acute Myeloid Leukemia.
Le Y; Fraineau S; Chandran P; Sabloff M; Brand M; Lavoie JR; Gagne R; Rosu-Myles M; Yauk CL; Richardson RB; Allan DS
Stem Cell Rev Rep; 2016 Apr; 12(2):235-44. PubMed ID: 26649729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
